

10613588

=> d his

(FILE 'HOME' ENTERED AT 10:23:20 ON 22 FEB 2005)

FILE 'REGISTRY' ENTERED AT 10:23:36 ON 22 FEB 2005

L1 STRUCTURE UPLOADED
L2 4 S L1
L3 127 S L1 SSS FULL


FILE 'CPLUS' ENTERED AT 10:24:29 ON 22 FEB 2005

L4 6 S L3

=> d 11

L1 HAS NO ANSWERS

L1 STR




G1 C,O,S,Cy

Structure attributes must be viewed using STN Express query preparation.

=> d 1-6 bib abs hitstr

L4 ANSWER 1 OF 6 CPLUS COPYRIGHT 2005 ACS on STN
AN 2005:34602 CPLUS
DN 142:134600
TI Preparation of pyrazoloisoquinolines as NF κ B-inducing kinase (NIK) inhibitors
IN Majid, Tahir Nadeem; Hopkins, Corey; Pedgrift, Brian Leslie; Collar, Nicola; Wirtz-Brugger, Friederike; Merrill, Jean
PA Aventis Pharmaceuticals Inc., USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
----- ----- ----- ----- -----
PI US 2005009859 A1 20050113 US 2003-613588 20030703
PRAI US 2003-613588
GI



AB Title compds. [I; A = (substituted) alkyl, heteroaryl, heterocycl; B = bond, C:CR1, C:tplbond.C, O(CH2)a, O, S, CO, NR2, NR2CO, (substituted) alkylene, etc.; R1 = H, alkyl, aryl, etc.; R2 = alkyl, OH, alkoxy, halo, etc.; a = 1-4; D = (substituted) alkyl, heteroaryl, heterocycl, aryl, cycloalkyl; BD = H, halo, fluoroalkyl, fluoroalkoxy, etc.; R = H, alkyl, (substituted) aralkyl; X, Z = H, alkyl, OH, alkoxy, halo, fluoroalkyl, CO2R1, N(R1)2, cyano, SR1, SOR1, SO2R1, (substituted) heterocycl,


cycloalkyl, etc.; with provisos], were prepared. Thus, hydroxybenzotriazole, diisopropyl carbodiimide, benzoic acid, and 3,5-diphenyl-1H-pyrazol-4-ylamine were stirred 12 h in MeCN to give a residue which was heated with P2O5 and POC13 in xylene at 150° for 4 h followed by stirring at room temperature for 12 h to give 3,5-diphenyl-1H-pyrazolo[4,3-c]isoquinoline. The latter inhibited TNF α release in LPS-stimulated human peripheral blood lymphocytes with IC50 = 1.9 nM.

IT 112884-48-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(claimed compound; preparation of pyrazoloisoquinolines as NF κ B-inducing kinase inhibitors)

RN 112884-48-7 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




IT 112884-54-5P 112884-56-7P 824968-16-3P
824968-17-4P 824968-18-5P 824968-19-6P
824968-20-9P 824968-21-0P 824968-22-1P
824968-23-2P 824968-24-3P 824968-25-4P
824968-26-5P 824968-27-6P 824968-28-7P
824968-29-8P 824968-30-1P 824968-31-2P
824968-32-3P 824968-33-4P 824968-34-5P
824968-35-6P 824968-36-7P 824968-37-8P
824968-38-9P 824968-39-0P 824968-40-3P
824968-41-4P 824968-42-5P 824968-43-6P
824968-44-7P 824968-45-8P 824968-46-9P
824968-47-0P 824968-48-1P 824968-49-2P
824968-50-5P 824968-51-6P 824968-52-7P
824968-53-8P 824968-54-9P 824968-55-0P
824968-56-1P 824968-57-2P 824968-58-3P
824968-59-4P 824968-60-7P 824968-61-8P
824968-62-9P 824968-63-0P 824968-64-1P
824968-65-2P 824968-66-3P 824968-67-4P
824968-68-5P 824968-69-6P 824968-70-9P
824968-71-0P 824968-72-1P 824968-73-2P
824968-74-3P 824968-75-4P 824968-76-5P
824968-77-6P 824968-78-7P 824968-79-8P
824968-80-1P 824968-81-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyrazoloisoquinolines as NF κ B-inducing kinase inhibitors)

RN 112884-54-5 CAPLUS


CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 112884-56-7 CAPLUS


10613588

CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(4-chlorophenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 824968-16-3 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-pyridinyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 824968-17-4 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 824968-18-5 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 824968-19-6 CAPLUS


CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 824968-20-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 1,3-dimethyl-5-[3-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)




RN 824968-21-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-phenyl-3-(trifluoromethyl)- (9CI) (CA
INDEX NAME)



RN 824968-22-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,6-difluorophenyl)-1,3-dimethyl- (9CI)
(CA INDEX NAME)




RN 824968-23-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-cyclohexyl-3-methyl-1-(phenylmethyl)-
(9CI) (CA INDEX NAME)




10613588


RN 824968-24-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-naphthalenyl)-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 824968-25-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(methoxymethyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 824968-26-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline-7-carboxylic acid, 3-methyl-5-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 824968-27-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline-7-carboxylic acid, 3-methyl-5-(2-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 824968-28-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinolin-7-amine, N,N,3-trimethyl-5-phenyl- (9CI) (CA INDEX NAME)


10613588




RN 824968-29-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinolin-7-amine, N,N,3-trimethyl-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 824968-30-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinolin-6-amine, N,N,3-trimethyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 824968-31-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinolin-6-amine, N,N,3-trimethyl-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 824968-32-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinolin-8-amine, N,N,3-trimethyl-5-phenyl- (9CI) (CA INDEX NAME)



10613588


RN 824968-33-4 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinolin-8-amine, N,N,3-trimethyl-5-(2-pyridinyl)-
(9CI) (CA INDEX NAME)




RN 824968-34-5 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 1,3-dimethyl-5-(3-methyl-2-thienyl)- (9CI)
(CA INDEX NAME)




RN 824968-35-6 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-phenyl-9-(trifluoromethyl)-
(9CI) (CA INDEX NAME)



RN 824968-36-7 CAPLUS


CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-pyridinyl)-9-
(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 824968-37-8 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(pentafluorophenyl)- (9CI) (CA
INDEX NAME)


10613588




RN 824968-38-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-benzo[b]thien-2-yl-3-methyl- (9CI) (CA INDEX NAME)



RN 824968-39-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7-bromo-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 824968-40-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7-bromo-3-methyl-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 824968-41-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3-chlorobenzo[b]thien-2-yl)-3-methyl- (9CI) (CA INDEX NAME)


10613588




RN 824968-42-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-chloro-3-pyridinyl)-3-methyl- (9CI)
(CA INDEX NAME)




RN 824968-43-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(6-chloro-3-pyridinyl)-3-methyl- (9CI)
(CA INDEX NAME)



RN 824968-44-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-ethyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 824968-45-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-ethyl-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




10613588


RN 824968-46-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-ethyl-5-(3-pyridinyl)- (9CI) (CA INDEX
NAME)




RN 824968-47-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-furanyl)-3-methyl- (9CI) (CA INDEX
NAME)



RN 824968-48-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7-methoxy-3-methyl-5-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 824968-49-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3-methyl-2-benzofuranyl)-
(9CI) (CA INDEX NAME)




RN 824968-50-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 6-chloro-3-methyl-5-phenyl- (9CI) (CA
INDEX NAME)


10613588




RN 824968-51-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 6-fluoro-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 824968-52-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 8-fluoro-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 824968-53-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 8-fluoro-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 824968-54-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 9-chloro-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




10613588


RN 824968-55-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 9-fluoro-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 824968-56-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3,9-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 824968-57-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 824968-58-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 824968-59-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-bromophenyl)-3-methyl- (9CI) (CA INDEX NAME)


10613588




RN 824968-60-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3-bromophenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 824968-61-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-chlorophenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 824968-62-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,4-dichlorophenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 824968-63-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3,4-dichlorophenyl)-3-methyl- (9CI) (CA INDEX NAME)


10613588




RN 824968-64-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,6-dichlorophenyl)-3-methyl- (9CI)
(CA INDEX NAME)



RN 824968-65-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-fluorophenyl)-3-methyl- (9CI) (CA
INDEX NAME)




RN 824968-66-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(4-fluorophenyl)-3-methyl- (9CI) (CA
INDEX NAME)




RN 824968-67-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,4-difluorophenyl)-3-methyl- (9CI)
(CA INDEX NAME)


10613588




RN 824968-68-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,6-difluorophenyl)-3-methyl- (9CI)
(CA INDEX NAME)




RN 824968-69-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 6-chloro-3-methyl-5-(2-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 824968-70-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 6-fluoro-3-methyl-5-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 824968-71-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 8-chloro-3-methyl-5-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




10613588


RN 824968-72-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 8-fluoro-3-methyl-5-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 824968-73-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 9-chloro-3-methyl-5-(2-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 824968-74-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 9-fluoro-3-methyl-5-(2-pyridinyl)- (9CI)
(CA INDEX NAME)




RN 824968-75-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3,9-dimethyl-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 824968-76-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(1-methyl-1H-pyrrol-2-yl)- (9CI) (CA INDEX NAME)


10613588




RN 824968-77-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-quinolinyl)- (9CI) (CA INDEX NAME)




RN 824968-78-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3-quinolinyl)- (9CI) (CA INDEX NAME)



RN 824968-79-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-quinoxaliny)- (9CI) (CA INDEX NAME)




RN 824968-80-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-thienyl)- (9CI) (CA INDEX NAME)



10613588

RN 824968-81-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3-methyl-2-thienyl)- (9CI)
(CA INDEX NAME)




IT 645417-67-0P 645417-68-1P 645417-69-2P
645417-70-5P 645417-71-6P 645417-72-7P
645417-73-8P 645417-74-9P 645417-75-0P
645417-76-1P 645417-77-2P 645417-78-3P
645417-79-4P 645417-80-7P 645417-81-8P
645417-82-9P 645417-83-0P 645417-84-1P
645417-85-2P 645417-86-3P 645417-87-4P
645417-88-5P 645417-89-6P 645417-90-9P
645417-91-0P 645417-92-1P 645417-93-2P
645417-94-3P 645417-95-4P 645417-96-5P
645417-97-6P 824968-82-3P 824968-83-4P
824968-84-5P 824968-85-6P 824968-86-7P
824968-87-8P 824968-88-9P 824970-41-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazoloisoquinolines as NF κ B-inducing kinase inhibitors)

RN 645417-67-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3,5-diphenyl- (9CI) (CA INDEX NAME)




RN 645417-68-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-69-2 CAPLUS
CN Phenol, 3-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)


10613588




RN 645417-70-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-71-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,3-dimethoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 645417-72-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,4-dimethoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-73-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,6-dimethoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




10613588


RN 645417-74-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3,4-dimethoxyphenyl)-3-methyl- (9CI)
(CA INDEX NAME)




RN 645417-75-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3,5-dimethoxyphenyl)-3-methyl- (9CI)
(CA INDEX NAME)



RN 645417-76-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2,3,4-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 645417-77-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2,4,6-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 645417-78-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)


10613588




RN 645417-79-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-ethoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-80-7 CAPLUS
CN Benzenamine, N,N-diethyl-4-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)



RN 645417-81-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 645417-82-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)




10613588


RN 645417-83-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 645417-84-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 645417-85-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 645417-86-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 645417-87-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7,8-dimethoxy-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)


10613588




RN 645417-88-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7-methoxy-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 645417-89-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7,8-dimethoxy-5-(3-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-90-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7,8-dimethoxy-3-methyl-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 645417-91-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7,8-dimethoxy-3-methyl-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)


10613588




RN 645417-92-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7-methoxy-5-(3-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-93-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline-3-carboxylic acid, 5-phenyl- (9CI) (CA INDEX NAME)



RN 645417-94-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline-3-carboxylic acid, 5-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 645417-95-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline-3-methanol, 5-phenyl- (9CI) (CA INDEX NAME)




10613588


RN 645417-96-5 CAPLUS
CN Phenol, 2-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)




RN 645417-97-6 CAPLUS
CN 1,3-Benzenediol, 5-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)



RN 824968-82-3 CAPLUS
CN 1,2-Benzenediol, 3-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)



RN 824968-83-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(5-isoxazolyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 824968-84-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,6-difluorophenyl)-3-methyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 824968-68-5
CMF C17 H11 F2 N3

10613588




CM 2


CRN 76-05-1
CMF C2 H F3 O2




RN 824968-85-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7-bromo-3-methyl-5-(3-pyridinyl)- (9CI)
(CA INDEX NAME)



RN 824968-86-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,5-dimethyl-3-furanyl)-3-methyl- (9CI)
(CA INDEX NAME)




RN 824968-87-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3-thienyl)- (9CI) (CA INDEX
NAME)



10613588


RN 824968-88-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-[2-(methylthio)-3-pyridinyl]-
(9CI) (CA INDEX NAME)



RN 824970-41-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-[3-(trifluoromethyl)phenyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 824968-18-5
CMF C18 H12 F3 N3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:41469 CAPLUS
DN 140:94041
TI Preparation of pyrazoloisoquinolines as NF κ B-inducing kinase (NIK) inhibitors

IN Flohr, Stefanie; Naumann, Thorsten
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2


DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005287	A1	20040115	WO 2003-EP6500	20030620
	WO 2004005287	C2	20040304		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				


RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 DE 10229762 A1 20040122 DE 2002-10229762 20020703
 US 2004097541 A1 20040520 US 2003-613482 20030703
 US 6841556 B2 20050111
 PRAI DE 2002-10229762 A 20020703
 US 2002-423954P P 20021105
 OS MARPAT 140:94041
 GI



AB Title compds. [I; A = alkyl substituted by 1-2 OR1, CO2R1, (substituted) heteroaryl; B = bond, R1-substituted alkylene; D = (substituted) heteroaryl, heterocyclyl, aryl, cycloalkyl; X, Y = H, alkyl, OH, alkoxy, halo; R1 = H, alkyl], were prepared Thus, PhCO2H, hydroxybenzotriazole, diisopropyl carbodiimide, and 3,5-diphenyl-1H-pyrazol-4-ylamine were stirred 12 h in MeCN to give a residue which was heated with P2O5 and POC13 in xylene at 150° for 4 h and at room temperature for 12 h to give 3,5-diphenyl-1H-pyrazolo[4,3-c]isoquinoline. The latter inhibited TNF α release in LPS-stimulated human peripheral blood lymphocytes with IC50 = 1.9 μ M.


IT 645417-67-0P 645417-68-1P 645417-69-2P
 645417-70-5P 645417-71-6P 645417-72-7P
 645417-73-8P 645417-74-9P 645417-75-0P
 645417-76-1P 645417-77-2P 645417-78-3P
 645417-79-4P 645417-80-7P 645417-81-8P
 645417-82-9P 645417-83-0P 645417-84-1P
 645417-85-2P 645417-86-3P 645417-87-4P
 645417-88-5P 645417-89-6P 645417-90-9P
 645417-91-0P 645417-92-1P 645417-93-2P
 645417-94-3P 645417-95-4P 645417-96-5P
 645417-97-6P 645417-98-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (claimed compound; preparation of pyrazoloisoquinolines as NIK inhibitors)

RN 645417-67-0 CAPLUS
 CN 1H-Pyrazolo[4,3-c]isoquinoline, 3,5-diphenyl- (9CI) (CA INDEX NAME)




RN 645417-68-1 CAPLUS
 CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)


10613588




RN 645417-69-2 CAPLUS
CN Phenol, 3-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)




RN 645417-70-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 645417-71-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,3-dimethoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-72-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,4-dimethoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




10613588


RN 645417-73-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2,6-dimethoxyphenyl)-3-methyl- (9CI)
(CA INDEX NAME)




RN 645417-74-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3,4-dimethoxyphenyl)-3-methyl- (9CI)
(CA INDEX NAME)



RN 645417-75-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(3,5-dimethoxyphenyl)-3-methyl- (9CI)
(CA INDEX NAME)




RN 645417-76-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2,3,4-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 645417-77-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2,4,6-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)


10613588




RN 645417-78-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3,4,5-trimethoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 645417-79-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-ethoxyphenyl)-3-methyl- (9CI) (CA
INDEX NAME)



RN 645417-80-7 CAPLUS
CN Benzenamine, N,N-diethyl-4-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)-
(9CI) (CA INDEX NAME)




RN 645417-81-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(4-pyridinyl)- (9CI) (CA INDEX
NAME)




10613588


RN 645417-82-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(3-pyridinyl)- (9CI) (CA INDEX
NAME)




RN 645417-83-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-pyridinyl)- (9CI) (CA INDEX
NAME)



RN 645417-84-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(phenylmethyl)- (9CI) (CA
INDEX NAME)




RN 645417-85-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(2-phenylethyl)- (9CI) (CA
INDEX NAME)




RN 645417-86-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(1-methyl-4-piperidinyl)- (9CI)
(CA INDEX NAME)


10613588




RN 645417-87-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7,8-dimethoxy-3-methyl-5-phenyl- (9CI)
(CA INDEX NAME)



RN 645417-88-5 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7-methoxy-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 645417-89-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7,8-dimethoxy-5-(3-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-90-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7,8-dimethoxy-3-methyl-5-(2-pyridinyl)- (9CI) (CA INDEX NAME)


10613588




RN 645417-91-0 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7,8-dimethoxy-3-methyl-5-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 645417-92-1 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 7-methoxy-5-(3-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 645417-93-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline-3-carboxylic acid, 5-phenyl- (9CI) (CA INDEX NAME)




RN 645417-94-3 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline-3-carboxylic acid, 5-phenyl-, methyl ester (9CI) (CA INDEX NAME)


10613588




RN 645417-95-4 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline-3-methanol, 5-phenyl- (9CI) (CA INDEX NAME)




RN 645417-96-5 CAPLUS
CN Phenol, 2-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)



RN 645417-97-6 CAPLUS
CN 1,3-Benzenediol, 5-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)




RN 645417-98-7 CAPLUS
CN 1,2-Benzenediol, 4-(3-methyl-1H-pyrazolo[4,3-c]isoquinolin-5-yl)- (9CI) (CA INDEX NAME)




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:246490 CAPLUS
DN 135:122430
TI Halogenation of pyrazoloquinolines and pyrazoloisoquinolines. Theoretical analysis of the regioreactivity and cross-coupling of 3-halogen derivatives
AU Pawlas, Jan; Greenwood, Jeremy; Vedso, Per; Liljefors, Tommy; Jakobsen, Palle; Huusfeldt, Per Olaf; Begtrup, Mikael
CS Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, Copenhagen, DK-2100, Den.
SO Journal of the Chemical Society, Perkin Transactions 1 (2001), (8), 861-866
CODEN: JCSPCE; ISSN: 1472-7781
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 135:122430
GI




AB Regioselective bromination and iodination of pyrazoloquinolines and pyrazoloisoquinolines I and II ($R = \text{benzyl}$, $R1 = H$, $X = N$, $Y = \text{CH}$; $R = \text{benzyl}$, $R1 = H$, $X = \text{CH}$, $Y = N$) to form the corresponding halopyrazoles I and II ($R1 = \text{Br}$, I) was discussed. Reactivity differences between I ($R = \text{benzyl}$, $R1 = H$, $X = N$, $Y = \text{CH}$), I ($R = \text{benzyl}$, $R1 = H$, $X = \text{CH}$, $Y = N$) and II ($R = \text{benzyl}$, $R1 = H$, $X = \text{CH}$, $Y = N$), and the failure of II ($R = \text{benzyl}$, $R1 = H$, $X = N$, $Y = \text{CH}$) to give the expected halopyrazoles, were explained using calculated relative energies of bromination, and inspection of frontier MOs. Utility of the prepared halides was demonstrated by a series of palladium-catalyzed cross-coupling reactions.


IT 351058-29-2P 351058-31-6P 351058-33-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(halogenation of pyrazoloquinolines and pyrazoloisoquinolines, theor.
anal. of bromination regioselectivity by HOMO calcn. and palladium
catalyzed cross-coupling of their 3-halogen derivs.)
RN 351058-29-2 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-(4-methylphenyl)-1-(phenylmethoxy)-
(9CI) (CA INDEX NAME)



RN 351058-31-6 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 1-(phenylmethoxy)-3-[1-(phenylmethoxy)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 351058-33-8 CAPLUS
 CN 1H-Pyrazolo[4,3-c]isoquinoline, 1-(phenylmethoxy)-3-
 [(trimethylsilyl)ethynyl]- (9CI) (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:392479 CAPLUS
 DN 131:157733
 TI Valence Bond Isomerization of Fused [1,2,3]Triazolium Salts with
 Bridgehead Nitrogen Atom. Fused Azolium Salts. 19
 AU Beres, Mariann; Hajos, Gyoergy; Riedl, Zsuzsanna; Soos, Tibor; Timari,
 Geza; Messmer, Andras
 CS Chemical Research Center Institute of Chemistry, Hungarian Academy of
 Sciences, Budapest, H-1525, Hung.
 SO Journal of Organic Chemistry (1999), 64(15), 5499-5503
 CODEN: JOCEAH; ISSN: 0022-3263
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 131:157733
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The tetrafluoroborate salts of triazoloquinolinium cation I, triazolo[1,5-b]isoquinolinium cation II, and [1,2,3]triazolo[1,5-a]pyrazinium cation III undergo valence bond isomerization when heated in either trifluoroacetic acid or in o-dichlorobenzene to ring-opened reactive intermediates which can participate in electrophilic substitution as nitrenium cations to yield pyrazole- and indazole-fused new heterocycles, pseudoelectrocyclization of nitrenium intermediates onto electron-deficient rings, or as carbenium cations in nucleophilic addition reactions. E.g., the tetrafluoroborate of II cyclized in o-dichlorobenzene at 190° to give the indazolylisoquinoline IV in 83% yield, while cyclization of II in CF₃CO₂H at reflux gave arylpyrazoloisoquinoline V in 85% yield. Comparison of these and some recent results reveals that this ring opening of fused [1,2,3]triazolium salts is a general phenomenon and is closely related to the well-known retro-electrocyclizations (called "1,5-dipolar cyclizations") of neutral fused [1,2,3]triazoles and tetrazoles.


IT 237417-80-OP 237417-84-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of fused pyrazole and indazole heterocycles by valence bond
 isomerization ring cleavage and regioselective intramol. cyclization
 reactions of fused triazolium salts)

RN 237417-80-0 CAPLUS
 CN 1H-Pyrazolo[4,3-c]isoquinoline, 1-(4-bromophenyl)-3-(4-chlorophenyl)-
 (9CI) (CA INDEX NAME)




RN 237417-84-4 CAPLUS
 CN 1H-Pyrazolo[4,3-c]isoquinoline, 1-(4-bromophenyl)-3-(2-thienyl)- (9CI)
 (CA INDEX NAME)

✓



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1990:20931 CAPLUS
 DN 112:20931
 TI Synthesis of 1,5-diaryl-3-methyl-1H-pyrazolo[4,5-c]isoquinolines and
studies of binding to specific peripheral benzodiazepine binding sites
 AU Cecchi, Lucia; Colotta, Vittoria; Melani, Fabrizio; Palazzino, Giovanna;
Filacchioni, Guido; Martini, Claudia; Giannaccini, Gino; Lucacchini,
Antonio
 CS Dip. Sci. Farm., Univ. Firenze, Florence, 50121, Italy
 SO Journal of Pharmaceutical Sciences (1989), 78(6), 437-42
CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English
 OS CASREACT 112:20931
 GI



AB Title compds. I (R = H, Me, Cl; R1 = H, Cl; X = CH, N) and II (R2 = Ph,

10613588


2-ClC₆H₄) were synthesized and tested for their ability to displace [3H]clonazepam or [3H]Ro 5-4864 from their specific binding on the central and peripheral benzodiazepine receptors. None of the tested compds. showed any activity as central binding inhibitors, while most of them were specific as peripheral binding inhibitors, although they were not very potent.

IT 124292-63-3P 124292-64-4P 124292-65-5P
124292-66-6P 124292-67-7P 124292-68-8P
124292-69-9P 124320-97-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and binding of, to specific peripheral benzodiazepine binding sites)


RN 124292-63-3 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-1,5-diphenyl- (9CI) (CA INDEX NAME)




RN 124292-64-4 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-chlorophenyl)-3-methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 124292-65-5 CAPLUS


CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-chlorophenyl)-3-methyl-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 124292-66-6 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-chloro-3-pyridinyl)-3-methyl-1-(3-methylphenyl)- (9CI) (CA INDEX NAME)


10613588




RN 124292-67-7 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 1-(3-chlorophenyl)-3-methyl-5-phenyl-
(9CI) (CA INDEX NAME)




RN 124292-68-8 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(2-chlorophenyl)-1-(3-chlorophenyl)-3-
methyl- (9CI) (CA INDEX NAME)



RN 124292-69-9 CAPLUS
CN 1H-Pyrazolo[4,3-c]isoquinoline, 1-(3-chlorophenyl)-5-(2-chloro-3-
pyridinyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 124320-97-4 CAPLUS
 CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-1-(3-methylphenyl)-5-phenyl-
 (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1988:94544 CAPLUS
 DN 108:94544
 TI Preparation of pyrazoloisoquinolines as antiinflammatory agents
 IN Tully, Wilfred Roger
 PA Roussel Laboratories Ltd., UK
 SO Brit. UK Pat. Appl., 11 pp.
 CODEN: BAXXDU

DT Patent
 LA English
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE
 ----- ----- ----- -----
 PI GB 2185255 A1 19870715 GB 1987-662 19870113
 GB 2185255 B2 19891206
 FR 2595096 A1 19870904 FR 1987-152 19870109
 FR 2595096 B1 19911129
 PRAI GB 1986-752 A 19860114
 OS CASREACT 108:94544
 GI



AB The title compds. I [R = H, (substituted) alkyl, alkenyl, cycloalkyl, haloalkyl; R3 = H, alkyl, aryl; R4 = (substituted) alkyl, alkenyl, cycloalkyl, (substituted) aryl; R5 = H, halo, alkyl, alkoxy, NO2], useful

as antiinflammatory agents, were prepared by cyclization of II in the presence of polyphosphoric acid. A mixture of 10 g 3-methyl-5-phenyl-4-pyrazolamine and 10 g PhCOCl in 100 mL CHCl₃ was stirred at room temperature for 30 min to give 12 g N-(3-methyl-5-phenyl-4-pyrazolyl)benzamide (III). A mixture of 9 g III and 90 g polyphosphoric acid was heated at 200-300° for 15-30 min to give 7 g pyrazoloisoquinoline derivative I (R = R₅ = H, R₃ = Me, R₄ = Ph) (IV). At 20 mg/kg orally, IV inhibited carageenin-induced edema in rats by 48%. Tablets containing IV, lactose, starch, talc, and Mg stearate were prepared

IT 112884-48-7P, 3-Methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline

112884-49-8P 112884-53-4P 112884-54-5P


112884-55-6P 112884-56-7P 112884-57-8P

112884-59-OP

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)


RN 112884-48-7 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 112884-49-8 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 1,3-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 112884-53-4 CAPLUS


CN 1H-Pyrazolo[4,3-c]isoquinoline, 3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 112884-54-5 CAPLUS


CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

10613588




RN 112884-55-6 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 112884-56-7 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(4-chlorophenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 112884-57-8 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 112884-59-0 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 1-(3-chloropropyl)-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)

10613588

